Technology Stocks Slide But Other Sectors Hold Up Better
at Investor's Business Daily - 2 hrs 44 mins ago
A harsh sell-off in the market Thursday did not spare many stocks in Your Weekly Review. Nearly every stock on the screen closed lower, and the selling affected certain sectors more than others. However, few leaders triggered outright sell signals....
Biogen Idec To Report Third Quarter 2014 Financial Results on October 22, 2014
Business Wire - Thu Sep 25, 4:34PM CDT
Biogen Idec Inc. (NASDAQ:BIIB) today announced it will report third quarter 2014 financial results on Wednesday, October 22, 2014, before the financial markets open.
Stocks Get Hit Hard; GoPro, Skechers Buck Weakness
at Investor's Business Daily - Thu Sep 25, 3:23PM CDT
Stocks suffered their biggest losses in nearly two months Thursday amid mixed data on weekly jobless claims and durable goods. Hurt by a near 4% drop in Apple (AAPL), the Nasdaq tumbled 1.9%. The S&P 500 lost 1.6%. Both indexes breached support at...
Wave Of Selling Hits Stocks; IPO CyberArk Extends Gains
at Investor's Business Daily - Thu Sep 25, 12:31PM CDT
Buyers were in short supply in early-afternoon trading Thursday as another wave of institutional selling hit the Nasdaq. The tech-laden index slumped 1.8%, weighed down by weakness in Apple (AAPL). The Dow Jones industrial average and S&P 500 lost...
Apple Fuels Tech Sell-Off; Valeant Bucks The Trend
at Investor's Business Daily - Thu Sep 25, 10:34AM CDT
Major averages were sharply lower two hours into Thursday's session. The Nasdaq slumped 1.7% as Apple cast a pall on the tech sector. The Dow Jones industrial average and S&P 500 lost 1.2% each, and small caps took another hit as the Russell 2000...
Stock Market News for September 25, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Thu Sep 25, 9:10AM CDT
Markets rebounded on Wednesday after taking losses in three straight sessions
Jim Cramer's 'Mad Money' Recap: Why You Can't Get Too Negative in This Market
at The Street - Wed Sep 24, 7:24PM CDT
Investors always need to be prepared for when common sense returns to the market, Cramer says.
Biogen Idec Set to Possibly Pullback After Yesterday's Rally of 4.23%
Comtex SmarTrend(R) - Wed Sep 24, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.11 to a high of $347.75. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $334.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
SmarTrend Watching for Potential Pullback in Shares of Biogen Idec After 4.23% Gain
Comtex SmarTrend(R) - Wed Sep 24, 3:46PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $333.11 to a high of $347.75. Yesterday, the shares gained 4.2%, which took the trading range above the 3-day high of $334.95 on volume of 1.5 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Stocks End Skid; Vertex, Alexion Lead Biotech Rebound
at Investor's Business Daily - Wed Sep 24, 3:16PM CDT
The major averages rose Wednesday, erasing most of the week's losses, aided by dovish comments from a top Federal Reserve official. The Nasdaq rose 1%, the Dow Jones industrial average 0.9% and the S&P 500 0.8%. Volume was mixed, rising 6% on the...
Stocks Up In Afternoon; Hasbro Jumps On Disney Deal
at Investor's Business Daily - Wed Sep 24, 2:05PM CDT
The major averages were hitting fresh intraday highs in late afternoon trading Wednesday, spurred by dovish comments from a top Federal Reserve policymaker. The Nasdaq and the Dow Jones industrial average each added 0.9%, while the S&P 500 picked up...
Acorda To Buy Civitas, Gains Parkinson's Disease Drug
at Investor's Business Daily - Wed Sep 24, 12:27PM CDT
Acorda Therapeutics (ACOR) stock popped after the biotechnology company agreed to buy privately held Civitas Therapeutics for $525 million, gaining access to drugs in late development used to treat Parkinson's disease. Acorda obtained global rights...
Stocks Hold Solid Gains; CyberArk Soars In Debut
at Investor's Business Daily - Wed Sep 24, 12:20PM CDT
Major averages held solid gains in early afternoon trading Wednesday. The Nasdaq added 0.6%, the Dow Jones industrial average rose 0.5% and the S&P 500 picked up 0.4%. NYSE volume was tracking slightly higher than Wednesday. Nasdaq volume was...
Results of Clinical Trials, New Drug Applications, Leadership Appointments, and Scheduled Earnings - Research Reports on Biogen, Salix, Express Scripts, Stryker and Shire
PR Newswire - Tue Sep 23, 8:25AM CDT
Today, Analysts Review released its research reports regarding Biogen Idec Inc. (NASDAQ: BIIB), Salix Pharmaceuticals Ltd. (NASDAQ: SLXP), Express Scripts Holding Company (NASDAQ: ESRX), Stryker Corporation (NYSE: SYK) and Shire plc. (NASDAQ: SHPG). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/6674-100free.
Biopharmaceutical and Vaccine Production Markets to 2018
M2 - Tue Sep 23, 8:21AM CDT
Research and Markets (http://www.researchandmarkets.com/research/h2pzn6/biopharmaceutical) has announced the addition of the "Biopharmaceutical and Vaccine Production Markets" report to their offering. Though biotechnology has created many new therapies and vaccines - including products to treat cancer, diabetes, HIV/AIDS and autoimmune disorders - there are still huge challenges during the final stages of clinical drug testing for new biopharmaceuticals, as manufacturers decide when and how to risk production capital to upscale while anticipating FDA or EMA approval. During the past five years, estimates for biopharmaceuticals have varied widely as analysts and producers have juggled the promise of new drugs with the technological and financial risks of manufacturing them efficiently. Biopharmaceutical and Vaccine Production Markets examines the total biopharmaceutical manufacturing market, including in its estimates all costs related to biopharmaceutical and vaccine production. It includes the following useful information for business planning: - Market Forecasts and Estimates of Biopharmaceutical Manufacturing Costs - Vaccine Production Estimates - Trend Discussion - Production Methods - The Competitive Environment, including Contract Manufacturing and Outsourcing - Regulation of the Market - Company Profiles The report contains production segmentations for the mammalian cell, microbial cell, monoclonal antibody, other recombinant protein, vaccine, and insulin manufacturing markets, with forecasts to 2018. The current competitive environment is noted, listing selected biopharmaceutical contract manufacturers, selected top-selling biopharmaceuticals, selected Asian biomanufacturing contract manufacturing organizations (CMOs), the top 10 biopharma companies based on 2012 biopharma revenues, and the top manufacturers by global biopharmaceutical manufacturing capacity. Report profiles of major contract manufacturers: - Lonza AG - Boehringer Ingelheim GmbH - FUJIFILM Diosynth Biotechnologies - Sandoz - Royal DSM - Rentschler Biotechnologie - Celonic - BIOMEVA GmbH - ProBioGen AG - Baxter BioPharma Solutions/Baxter Bioscience Major biologics firms : - Amgen - Genentech/Roche - AbbVie Inc. (Abbott) - Biogen Idec - Regeneron Pharmaceuticals - Alexion Pharmaceuticals - Crucell /Johnson & Johnson - GlaxoSmithKline - Merck & Co. Inc - Novartis - Pfizer - Sanofi Pasteur Other contract manufacturers profiled - AAIPharma - A-Bio Pharma Pte Ltd. - ABL, Inc. - Affinity Life Sciences, Inc. - Ajinomoto Aminoscience, LLC - Alliance Medical Products, Inc. - Alpha Biologics - Biotecnol - Boston Mountain Biotech - Glycobia - Sutro Biopharma Key Topics Covered: - Executive Summary - Commercial Production - Forecasts - Regulation - Competitive Environment - Patents - Geography - Profiles For more information visit http://www.researchandmarkets.com/research/h2...maceutical
Biogen Idec Named Global Biotechnology Industry Leader on Dow Jones Sustainability World Index
Business Wire - Tue Sep 23, 7:00AM CDT
Biogen Idec (NASDAQ:BIIB) has been named the biotechnology industry leader on the Dow Jones Sustainability World Index (DJSI World). The company also was named to the Dow Jones Sustainability Index (DJSI) North America for the fifth consecutive year, one of only two biotech companies included. In September 2013, Biogen Idec became the first U.S.-based biotechnology company to be named to DJSI World.
Olivier Danos Joins Biogen Idec as Senior Vice President, Gene Therapy
Business Wire - Tue Sep 23, 6:00AM CDT
Biogen Idec (NASDAQ:BIIB) today announced that Olivier Danos, Ph.D., has joined the company as senior vice president, Gene Therapy. Dr. Danos reports directly to Douglas Williams, Ph.D., executive vice president, Research and Development, and is a member of Biogen Idec's Senior Research and Development Leadership Team.
Most Big Cap 20 Stocks Near Entries, But Risks Exist
at Investor's Business Daily - Mon Sep 22, 6:05PM CDT
Most of the Big Cap 20 stocks are in buy ranges or forming bases. That's an unusually good trend that affords investors plenty of opportunities to deploy capital. But a sluggish market poses risks for any new purchases. For those willing to risk...
Isis Pharmaceuticals Up on $4M Milestone Payment - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:40PM CDT
Isis Pharmaceuticals, Inc. (ISIS) earned a $4 million milestone payment from Achaogen (AKAO), following the initiation of a phase III study on plazomicin.
Gilead's (GILD) Zydelig Gets EU Clearance for Blood Cancer - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Sep 22, 4:20PM CDT
The European Commission has approved Gilead's (GILD) Zydelig for the treatment of CLL and FL.